Lilly and Synthes Sign Collaboration Agreement

Eli Lilly and Co. has signed a deal with Synthes to co-promote the bone drug Forteo and develop other potential orthopedic treatments.

Drugmaker Eli Lilly has signed a worldwide collaboration agreement with Swiss medical device manufacturer Synthes Inc. to address the needs of patients with bone disorders.

The agreement will allow the joint development of early stage compounds to be used by patients in the care of orthopaedic surgeons, including those who suffer from osteoporosis, and the two companies will collaborate to develop osteoinductive medications.

Both companies will also conduct and fund work into evaluating Lilly's osteoporosis drug Forteo for other orthopaedic uses, while Forteo will also be co-promoted in the US to orthopaedic surgeons under the agreement.

Lilly Bio-Medicines ex